Quarterly ResultAug 6, 2026, 04:40 PM
Structure Therapeutics Q2 Net Loss $(106.2)M; R&D up 83%
AI Summary
Structure Therapeutics Inc. reported a net loss of $(106.2) million for the three months ended June 30, 2026, an increase from $(61.7) million in the prior year period, driven by higher research and development expenses. The company's cash, cash equivalents, and short-term investments stood at $1.34 billion as of June 30, 2026, and it anticipates these funds will be sufficient to support operations for at least the next 12 months. This liquidity was bolstered by a $701.5 million net proceeds from a 2025 follow-on offering and an amended at-the-market offering program allowing for up to $400.0 million in additional sales.
Key Highlights
- Net loss for Q2 2026 was $(106.2) million, up from $(61.7) million in Q2 2025.
- Net loss per share for Q2 2026 was $(0.49), compared to $(0.36) in Q2 2025.
- Research and development expenses increased to $100.1 million in Q2 2026 from $54.7 million in Q2 2025.
- Cash, cash equivalents, and short-term investments totaled $1.34 billion as of June 30, 2026.
- Company expects current cash, cash equivalents, and short-term investments to fund operations for at least 12 months.
- Amended ATM Sales Agreement allows offering up to $400.0 million, with $341.5 million remaining available.
- The 2025 Follow-On Offering closed in December 2025, generating approximately $701.5 million in net proceeds.
Price Impact
More from GPCR